Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203885 · ClinicalTrials.gov registry record · NA
AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment
A NA study, sponsored by Harvard Medical School (HMS and HSDM).
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT07203885: Completed NA study, sponsored by Harvard Medical School (HMS and HSDM).
NCT07203885 is a NA study that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07203885, a NA study, has completed, sponsored by Harvard Medical School (HMS and HSDM).
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will test whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Doctors usually examine bone marrow samples under a microscope to make this diagnosis, but it can be challenging and time-consuming. In this study, doctors will review bone marrow samples under three different conditions: * Unaided Review: Without AI assistance. * AI as Double-Check: AI-generated evaluation shown after the doctor makes an initial decision. * AI as First Look: AI-generated evaluation shown at the start of the review. Doctors will be randomly assigned to different orders of these three conditions. This design will allow us to compare how AI support affects diagnostic accuracy, speed, and confidence.
Primary Outcome
Performance of clinicians (unaided and AI-assisted) in detecting APL, measured in accuracy, sensitivity, specificity, positive predictive value, and negative predictive value.
Interventions
- BEHAVIORAL Unaided Review First, Then AI-Assisted Review
- BEHAVIORAL AI-Assisted Review First, Then Unaided Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2025-10-10 |
| Phase | NA |
What the finished NCT07203885 record still lists
NCT07203885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Unaided Review First, Then AI-Assisted Review is the first listed.
NCT07203885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07203885 about?
NCT07203885 is a clinical study titled "AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment". This study will test whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Doctors usually examine bone marrow samples under a microscope to make this diagnosis, but it can be challenging and time-con...
What is the current status of trial NCT07203885?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2025-09-09. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT07203885?
The interventions under investigation include: Unaided Review First, Then AI-Assisted Review (BEHAVIORAL), AI-Assisted Review First, Then Unaided Review (BEHAVIORAL).
Who is sponsoring clinical trial NCT07203885?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07203885's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI